{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:35:42Z","timestamp":1773081342094,"version":"3.50.1"},"reference-count":19,"publisher":"American Diabetes Association","issue":"4","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,4,1]]},"abstract":"<jats:p>OBJECTIVE\u2014We sought to assess health-related quality of life (HRQOL) in patients with type 2 diabetes treated with insulin glargine or rosiglitazone as add-on therapy to sulfonylurea plus metformin.<\/jats:p>\n               <jats:p>RESEARCH DESIGN AND METHODS\u2014HRQOL was evaluated in 217 subjects uncontrolled with sulfonylurea plus metformin, enrolled in a 24-week, multicenter, randomized, open-label, parallel-group trial of add-on insulin glargine versus rosiglitazone. A 40-item, self-administered questionnaire at baseline and at weeks 2, 6, 12, 18, and 24 was given, including the 34-item Diabetes Symptom Checklist-Revised (DSC-R), a 5-item mental health scale from the 36-item Short-Form Health Survey (SF-36), and a single-item health rating from the SF-36. These assessments do not specify route of therapy.<\/jats:p>\n               <jats:p>RESULTS\u2014Both treatment groups showed similar improvements in glycemic control from baseline to week 24 (change in A1C: \u22121.66% in the insulin glargine group, \u22121.51% in the rosiglitazone group, P = 0.1446). Both groups also showed improvement in HRQOL, although subjects treated with insulin glargine experienced significantly greater improvements compared with rosiglitazone in the DSC-R total symptom score (P = 0.005), total symptom distress score (P = 0.03), individual domain scores for mood symptoms (P = 0.007), ophthalmologic symptoms (P = 0.007), ophthalmologic distress (P = 0.013), fatigue distress (P = 0.033), and SF-36 perception of general health (P = 0.047).<\/jats:p>\n               <jats:p>CONCLUSIONS\u2014Although addition of insulin glargine and rosiglitazone achieved comparable improvements in glycemic control, insulin glargine was associated with greater improvements in HRQOL, indicating that other factors (e.g., safety profile and nonglycemic actions) may further enhance HRQOL in patients with type 2 diabetes.<\/jats:p>","DOI":"10.2337\/dc06-1712","type":"journal-article","created":{"date-parts":[[2007,3,29]],"date-time":"2007-03-29T00:15:25Z","timestamp":1175127325000},"page":"795-800","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":42,"title":["Adding Insulin Glargine Versus Rosiglitazone"],"prefix":"10.2337","volume":"30","author":[{"given":"Aaron I.","family":"Vinik","sequence":"first","affiliation":[{"name":"Strelitz Diabetes Research Institutes, Eastern Virginia Medical School, Norfolk, Virginia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanwu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes, Sanofi-Aventis U.S., Bridgewater, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","reference":[{"key":"2022031218053247100_R1","doi-asserted-by":"crossref","unstructured":"The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med\u2008329: 977\u2013986, 1993","DOI":"10.1056\/NEJM199309303291401"},{"key":"2022031218053247100_R2","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet\u2008352:837\u2013853, 1998","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"2022031218053247100_R3","doi-asserted-by":"crossref","unstructured":"Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA\u2008281:2005\u20132012, 1999","DOI":"10.1001\/jama.281.21.2005"},{"key":"2022031218053247100_R4","doi-asserted-by":"crossref","unstructured":"Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, for the U.K. Prospective Diabetes Study Group: Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care\u200825:330\u2013336, 2002","DOI":"10.2337\/diacare.25.2.330"},{"key":"2022031218053247100_R5","doi-asserted-by":"crossref","unstructured":"Hunt LM, Valenzuela MA, Pugh JA: NIDDM patients' fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care\u200820:292\u2013298, 1997","DOI":"10.2337\/diacare.20.3.292"},{"key":"2022031218053247100_R6","doi-asserted-by":"crossref","unstructured":"Korytkowski M: When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord\u200826 (Suppl. 3):S18\u2013S24, 2002","DOI":"10.1038\/sj.ijo.0802173"},{"key":"2022031218053247100_R7","doi-asserted-by":"crossref","unstructured":"Goddijn PPM, Bilo HJG, Feskens EJM, Groeniert KH, van der Zee KI, Meyboom-de Jong B: Longitudinal study on glycaemic control and quality of life in patients with type 2 diabetes mellitus referred for intensified control. Diabet Med\u200816:23\u201330, 1999","DOI":"10.1046\/j.1464-5491.1999.00002.x"},{"key":"2022031218053247100_R8","doi-asserted-by":"crossref","unstructured":"Pibernik-Okanovic\u0301 M, Szabo S, Metelko Z\u030c: Quality of life following a change in therapy for diabetes mellitus. Pharmacoeconomics\u200814:201\u2013207, 1998","DOI":"10.2165\/00019053-199814020-00008"},{"key":"2022031218053247100_R9","doi-asserted-by":"crossref","unstructured":"Fischer JS, McLaughlin T, Loza L, Beauchamp R, Schwartz S, Kipnes M: The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study. Curr Med Res Opin\u200820:1703\u20131710, 2004","DOI":"10.1185\/030079904X5526"},{"key":"2022031218053247100_R10","doi-asserted-by":"crossref","unstructured":"de Sonnaville JJJ, Snoek FJ, Colly LP, Deville\u0301 W, Wijkel D, Heine RJ: Well-being and symptoms in relation to insulin therapy in type 2 diabetes. Diabetes Care\u200821:919\u2013924, 1998","DOI":"10.2337\/diacare.21.6.919"},{"key":"2022031218053247100_R11","doi-asserted-by":"crossref","unstructured":"Davis TME, Clifford RM, Davis WA: Effect of insulin therapy on quality of life in type 2 diabetes mellitus: the Fremantle Diabetes Study. Diabetes Res Clin Pract\u200852:63\u201371, 2001","DOI":"10.1016\/S0168-8227(00)00245-X"},{"key":"2022031218053247100_R12","doi-asserted-by":"crossref","unstructured":"U.K. Prospective Diabetes Study Group: Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care\u200822:1125\u20131136, 1999","DOI":"10.2337\/diacare.22.7.1125"},{"key":"2022031218053247100_R13","doi-asserted-by":"crossref","unstructured":"Strowig SM, Avile\u0301s-Santa ML, Raskin P: Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care\u200827:1577\u20131583, 2004","DOI":"10.2337\/diacare.27.7.1577"},{"key":"2022031218053247100_R14","doi-asserted-by":"crossref","unstructured":"LeRoith D, Fonseca V, Vinik A: Metabolic memory in diabetes-focus on insulin. Diabete Metab Res Rev\u200821:85\u201390, 2005","DOI":"10.1002\/dmrr.530"},{"key":"2022031218053247100_R15","doi-asserted-by":"crossref","unstructured":"Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G, on behalf of the Insulin Glargine 4014 Study Investigators: Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-nai\u0308ve patients. Diabetes Care\u200829:554\u2013559, 2006","DOI":"10.2337\/diacare.29.03.06.dc05-0695"},{"key":"2022031218053247100_R16","doi-asserted-by":"crossref","unstructured":"Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM: Development of a type 2 diabetes symptom checklist: a measure of symptom severity. Diabet Med\u200811:253\u2013261, 1994","DOI":"10.1111\/j.1464-5491.1994.tb00268.x"},{"key":"2022031218053247100_R17","doi-asserted-by":"crossref","unstructured":"Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care\u200830:473\u2013483, 1992","DOI":"10.1097\/00005650-199206000-00002"},{"key":"2022031218053247100_R18","doi-asserted-by":"crossref","unstructured":"Hu L-T, Bentler P: Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Structural Equation Modeling\u20086:1\u201355, 1999","DOI":"10.1080\/10705519909540118"},{"key":"2022031218053247100_R19","doi-asserted-by":"crossref","unstructured":"Vinik EJ, Hayes RP, Oglesby A, Bastyr E, Barlow P, Ford-Molvik SL, Vinik AI: The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther\u20087:497\u2013508, 2005","DOI":"10.1089\/dia.2005.7.497"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/30\/4\/795\/596154\/zdc00407000795.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/30\/4\/795\/596154\/zdc00407000795.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T19:02:18Z","timestamp":1647111738000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/30\/4\/795\/25726\/Adding-Insulin-Glargine-Versus-RosiglitazoneHealth"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,1]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc06-1712","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,1]]}}}